Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD001 with or without zoledronic acid for renal cell carcinoma with bone metastases
ACTRN12609000980235Phase 2Completed
- Sponsor
- Auckland UniServices
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in renal cell carcinoma (RCC) comparing everolimus + zoledronic acid with everolimus (2 arms). Primary endpoint: Control of bone metastases measured by urinary N-telopeptide. Started Jan 2010; status: completed.
02
Drugs
everolimuszoledronic acid
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ACTRN12609000980235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000980235.